Login to Your Account



Financings Roundup

Tesaro Scores Biggest 2011 VC Round with $101M Series B

By Tom Wall


Wednesday, June 22, 2011
In the largest Series B financing of the year – and what appears to be the largest biotech venture financing for any round in 2011 – privately held oncology start-up Tesaro Inc. raised $101 million to advance lead candidate rolapitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting, and a small-molecule inhibitor of anaplastic lymphoma kinase.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription